Cingulate Therapeutics has reported positive results from its first in-human proof-of-concept trial of CTX-1301 in comparison with Focalin XR for the treatment of attention deficit hyperactivity disorder (ADHD).

The trial was designed to assess the pharmacokinetics and delivery mechanism of CTX-1301, using a new erosion barrier technology, OralogiK, which is developed by the UK-based company’s Bio-Images Drug Delivery (BDD).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It comprises three treatment arms including Focalin XR, CTX-1301 with a radiolabelled second layer, and CTX-1301 with a radiolabelled third layer.

During the trial, pharmacoscintigraphy monitored transit of the radiolabelled tablets through the gastrointestinal tract.

The trial also showed a mean time of 10.3 hours to the final release of CTX-1301, providing a statistically significant difference between the mean AUC eight to 24 hours post-dosing of the two CTX-1301 treatment groups and that of Focalin XR (17.05ng-hr/mL).

Improvement in the mean time has also confirmed higher blood plasma drug levels with CTX-1301 versus Focalin XR.

“We’ve been able to gain valuable insight as to how our assets are expected to perform in-vivo.”

During the study, CTX-1301 also offered a smoother, controlled descent of dexmethylphenidate hydrochloride (d-MPH) after the final dose as compared to Focalin XR.

Overall, the study showed that CTX-1301 delivered a consistent tri-modal release of the d-MPH and extended its blood plasma levels by four hours when compared with Focalin XR’s bi-phasic release of d-MPH.

Cingulate Therapeutics chairman and CEO Shane Schaffer said: “Before Cingulate Therapeutics embarks on the studies necessary to gain FDA approval, we’ve been able to gain valuable insight as to how our assets are expected to perform in-vivo.

“We are now preparing our investigational new drug (IND) filings for our lead ADHD products even as these results indicate the ability of our platform to deliver precisely timed doses for a wide range of therapeutic agents.”

Cingulate further will implement a full clinical plan for CTX-1301, a stimulant medication for the treatment of ADHD within this year.